Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

Similar articles for PubMed (Select 3212439)

1.

Obstacles to developing vaccines for the Third World.

Robbins A, Freeman P.

Sci Am. 1988 Nov;259(5):126-33.

PMID:
3212439
2.

Developing R&D portfolio business validity simulation model and system.

Yeo HJ, Im KH.

ScientificWorldJournal. 2015;2015:348369. doi: 10.1155/2015/348369. Epub 2015 Mar 29.

3.

Grants available: Gates Foundation seeks innovative concepts for animal vaccines.

[No authors listed]

Vet Rec. 2014 Nov 15;175(19):468. doi: 10.1136/vr.g6772. No abstract available.

PMID:
25395557
4.

Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways.

Crager SE.

Am J Public Health. 2014 Nov;104(11):e85-91. doi: 10.2105/AJPH.2014.302236. Epub 2014 Sep 11.

PMID:
25211753
5.

Global vaccine supply. The increasing role of manufacturers from middle income countries.

Francis DP, Du YP, Precioso AR.

Vaccine. 2014 Sep 15;32(41):5259-65. doi: 10.1016/j.vaccine.2014.07.069. Epub 2014 Aug 8.

PMID:
25110294
6.
7.

Using adhesives as a means to reduce costs and increase performance in the production of photovoltaic electricity.

Thorey C.

Chimia (Aarau). 2013;67(10):729-31. doi: 10.2533/chimia.2013.729.

PMID:
24388139
8.

Sleeping with the enemy: the United Nations Development Programme and its position on the non-communicable disease epidemic.

Jacob AG, Lal PG, Buragohain A.

Trop Med Int Health. 2014 Feb;19(2):136-9. doi: 10.1111/tmi.12236. Epub 2014 Jan 2.

9.

Drug versus vaccine investment: a modelled comparison of economic incentives.

R├ęgnier SA, Huels J.

Cost Eff Resour Alloc. 2013 Sep 8;11(1):23. doi: 10.1186/1478-7547-11-23.

10.

Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.

Pagliusi S, Leite LC, Datla M, Makhoana M, Gao Y, Suhardono M, Jadhav S, Harshavardhan GV, Homma A.

Vaccine. 2013 Apr 18;31 Suppl 2:B176-83. doi: 10.1016/j.vaccine.2012.11.060. Review.

PMID:
23598479
11.

The new vaccine frontier.

Gerberding JL.

S D Med. 2013;Spec no:123-6. Review.

PMID:
23444603
12.

Understanding the syndrome of techno-centrism through the epidemiology of vaccines as preventive tools.

Bajpai V, Saraya A.

Indian J Public Health. 2012 Apr-Jun;56(2):133-9. doi: 10.4103/0019-557X.99904.

13.

Biologic vaccines: a panacea for infectious diseases?

Adams KT.

Biotechnol Healthc. 2009 Apr;6(1):12-20.

14.

Convergence in the midst of competition.

Carroll J.

Biotechnol Healthc. 2007 Dec;4(6):31-40.

15.

Affordably priced new drugs for poor populations: Approaches for a global solution.

Mossialos E, Dukes G.

Int J Risk Saf Med. 2001;14(1):1-29.

PMID:
22388482
16.

Economical value of vaccines for the developing countries--the case of Instituto Butantan, a public institution in Brazil.

Ho PL, Miyaji EN, Oliveira ML, Dias Wde O, Kubrusly FS, Tanizaki MM, Martins EA, Raw I.

PLoS Negl Trop Dis. 2011 Nov;5(11):e1300. doi: 10.1371/journal.pntd.0001300. Epub 2011 Nov 29. Review. No abstract available.

17.

Economic perspectives on the advance market commitment for pneumococcal vaccines.

Snyder CM, Begor W, Berndt ER.

Health Aff (Millwood). 2011 Aug;30(8):1508-17. doi: 10.1377/hlthaff.2011.0403.

18.

Non-communicable diseases--finally on the global agenda.

Wielgosz AT.

Chronic Dis Inj Can. 2011 Jun;31(3):95-6.

19.

The future of immunisation policy, implementation, and financing.

Levine OS, Bloom DE, Cherian T, de Quadros C, Sow S, Wecker J, Duclos P, Greenwood B.

Lancet. 2011 Jul 30;378(9789):439-48. doi: 10.1016/S0140-6736(11)60406-6. Epub 2011 Jun 12.

PMID:
21664676
20.

Vaccine supply chains need to be better funded and strengthened, or lives will be at risk.

Kaufmann JR, Miller R, Cheyne J.

Health Aff (Millwood). 2011 Jun;30(6):1113-21. doi: 10.1377/hlthaff.2011.0368.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk